TWI609869B - 二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽 - Google Patents
二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽 Download PDFInfo
- Publication number
- TWI609869B TWI609869B TW102101537A TW102101537A TWI609869B TW I609869 B TWI609869 B TW I609869B TW 102101537 A TW102101537 A TW 102101537A TW 102101537 A TW102101537 A TW 102101537A TW I609869 B TWI609869 B TW I609869B
- Authority
- TW
- Taiwan
- Prior art keywords
- pyrrolo
- fluoro
- imidazol
- dihydro
- benzonitrile
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 76
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 title abstract description 7
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 title abstract description 7
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 title 1
- 239000003886 aromatase inhibitor Substances 0.000 title 1
- 125000002883 imidazolyl group Chemical group 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 58
- 239000010452 phosphate Substances 0.000 claims abstract description 57
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 54
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims abstract description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 49
- 238000002844 melting Methods 0.000 claims description 33
- 230000008018 melting Effects 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 20
- 229910002651 NO3 Inorganic materials 0.000 claims description 19
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 18
- 239000012458 free base Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- 238000010586 diagram Methods 0.000 claims description 9
- -1 3-fluoro-benzonitrile phosphate Chemical compound 0.000 claims description 7
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims description 7
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003586 protic polar solvent Substances 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- 238000002411 thermogravimetry Methods 0.000 claims description 2
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 claims 3
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims 3
- KXDCPYOPAFSXLI-UHFFFAOYSA-N 3-fluoro-2-(1h-imidazol-5-yl)benzonitrile Chemical compound FC1=CC=CC(C#N)=C1C1=CN=CN1 KXDCPYOPAFSXLI-UHFFFAOYSA-N 0.000 claims 1
- JZTPKAROPNTQQV-UHFFFAOYSA-N 3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1 JZTPKAROPNTQQV-UHFFFAOYSA-N 0.000 claims 1
- DMEHXNBFUVYAST-UHFFFAOYSA-N P(=O)(O)(O)O.FC1=C(C#N)C=CC=C1 Chemical compound P(=O)(O)(O)O.FC1=C(C#N)C=CC=C1 DMEHXNBFUVYAST-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 201000010099 disease Diseases 0.000 abstract description 24
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 125000003118 aryl group Chemical group 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 235000021317 phosphate Nutrition 0.000 description 50
- 229940126062 Compound A Drugs 0.000 description 46
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 46
- 150000001875 compounds Chemical class 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108090000028 Neprilysin Proteins 0.000 description 4
- 102000003729 Neprilysin Human genes 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000012296 anti-solvent Substances 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229960002478 aldosterone Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- GSQBAIGCFNYCSI-UHFFFAOYSA-N 2-(6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1C1N2C=NC=C2CC1 GSQBAIGCFNYCSI-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 description 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261587280P | 2012-01-17 | 2012-01-17 | |
| US61/587,280 | 2012-01-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201335161A TW201335161A (zh) | 2013-09-01 |
| TWI609869B true TWI609869B (zh) | 2018-01-01 |
Family
ID=47604250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102101537A TWI609869B (zh) | 2012-01-17 | 2013-01-15 | 二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽 |
Country Status (40)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011205290C1 (en) * | 2010-01-14 | 2014-11-06 | Recordati Ag | Use of an adrenal hormone-modifying agent |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| SI3166596T1 (sl) * | 2014-07-07 | 2018-10-30 | Novartis Ag | Farmacevtske odmerne oblike |
| HUE054248T2 (hu) | 2015-01-29 | 2021-08-30 | Recordati Ag | Eljárás kondenzált imidazo-származékok elõállítására |
| US20160287565A1 (en) * | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| EP3532056A1 (en) * | 2016-10-27 | 2019-09-04 | Damian Pharma AG | Aldosterone synthase inhibitor |
| WO2018078049A1 (en) * | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| WO2019211394A1 (en) | 2018-05-03 | 2019-11-07 | Damian Pharma Ag | R-fadrozole for use in the treatment of aldostonerism |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011088188A1 (en) * | 2010-01-14 | 2011-07-21 | Novartis Ag | Use of an adrenal hormone-modifying agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1315449A (en) * | 1918-11-15 | 1919-09-09 | Frank B Yingling | Shaper-feed. |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US5066656A (en) | 1989-11-01 | 1991-11-19 | Janssen Pharmaceutica N.V. | Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives |
| MTP1076B (en) | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| CA2127689A1 (en) | 1992-01-27 | 1993-08-05 | Marcel A. C. Janssen | Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors |
| CA2505752A1 (en) | 2002-11-18 | 2004-06-03 | Novartis Ag | Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| CN101578272A (zh) | 2006-12-18 | 2009-11-11 | 诺瓦提斯公司 | 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途 |
| US8575160B2 (en) | 2009-11-30 | 2013-11-05 | Novartis Ag | Imidazole derivatives as aldosterone synthase inhibitors |
-
2013
- 2013-01-15 IN IN6781DEN2014 patent/IN2014DN06781A/en unknown
- 2013-01-15 JP JP2014552375A patent/JP5749410B2/ja active Active
- 2013-01-15 UA UAA201406492A patent/UA114803C2/uk unknown
- 2013-01-15 HR HRP20160178T patent/HRP20160178T1/hr unknown
- 2013-01-15 SI SI201330142A patent/SI2804863T1/sl unknown
- 2013-01-15 ES ES13701194.6T patent/ES2564143T3/es active Active
- 2013-01-15 DK DK13701194.6T patent/DK2804863T3/en active
- 2013-01-15 PE PE2014001112A patent/PE20142358A1/es not_active Application Discontinuation
- 2013-01-15 JO JOP/2013/0014A patent/JO3137B1/ar active
- 2013-01-15 AU AU2013209952A patent/AU2013209952B2/en active Active
- 2013-01-15 TW TW102101537A patent/TWI609869B/zh not_active IP Right Cessation
- 2013-01-15 BR BR112014017260A patent/BR112014017260A8/pt not_active Application Discontinuation
- 2013-01-15 AR ARP130100119A patent/AR089728A1/es unknown
- 2013-01-15 NZ NZ626277A patent/NZ626277A/en not_active IP Right Cessation
- 2013-01-15 UY UY0001034576A patent/UY34576A/es not_active Application Discontinuation
- 2013-01-15 RS RS20160109A patent/RS54589B1/sr unknown
- 2013-01-15 EA EA201491374A patent/EA026232B1/ru not_active IP Right Cessation
- 2013-01-15 KR KR1020147016954A patent/KR20140093726A/ko not_active Ceased
- 2013-01-15 WO PCT/US2013/021521 patent/WO2013109514A1/en not_active Ceased
- 2013-01-15 MX MX2014008686A patent/MX2014008686A/es unknown
- 2013-01-15 CA CA2863339A patent/CA2863339C/en active Active
- 2013-01-15 HU HUE13701194A patent/HUE026984T2/en unknown
- 2013-01-15 AP AP2014007762A patent/AP2014007762A0/xx unknown
- 2013-01-15 PL PL13701194T patent/PL2804863T3/pl unknown
- 2013-01-15 US US14/370,124 patent/US9334276B2/en active Active
- 2013-01-15 EP EP13701194.6A patent/EP2804863B1/en active Active
- 2013-01-15 CN CN201380005054.0A patent/CN104039793B/zh active Active
- 2013-01-15 SG SG11201404061YA patent/SG11201404061YA/en unknown
- 2013-01-15 KR KR20147030158A patent/KR20140141687A/ko not_active Ceased
-
2014
- 2014-06-11 ZA ZA2014/04314A patent/ZA201404314B/en unknown
- 2014-06-12 TN TNP2014000256A patent/TN2014000256A1/en unknown
- 2014-07-07 IL IL233541A patent/IL233541B/en active IP Right Grant
- 2014-07-08 CO CO14146898A patent/CO7000775A2/es unknown
- 2014-07-11 MA MA37199A patent/MA35858B1/fr unknown
- 2014-07-15 CU CU2014000086A patent/CU20140086A7/es unknown
- 2014-07-15 CL CL2014001863A patent/CL2014001863A1/es unknown
- 2014-07-17 PH PH12014501638A patent/PH12014501638A1/en unknown
- 2014-07-17 CR CR20140345A patent/CR20140345A/es unknown
- 2014-07-17 GT GT201400155A patent/GT201400155A/es unknown
-
2016
- 2016-02-09 US US15/018,953 patent/US20160176883A1/en not_active Abandoned
- 2016-02-26 CY CY20161100163T patent/CY1117914T1/el unknown
- 2016-03-23 SM SM201600083T patent/SMT201600083B/xx unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011088188A1 (en) * | 2010-01-14 | 2011-07-21 | Novartis Ag | Use of an adrenal hormone-modifying agent |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5749410B2 (ja) | ジヒドロピロロ［１，２−ｃ］イミダゾリルアルドステロンシンターゼまたはアロマターゼ阻害薬の新たな形態および塩 | |
| ES2556764T3 (es) | [4-(5-Aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxietil)-4-trifluorometoxi-1H-indol-3-il]metanona como inhibidor de triptasa de mastocitos | |
| JP2021504310A (ja) | 血漿カリクレイン阻害剤及びその塩の固体形態 | |
| JP2009544602A (ja) | サイクリン依存性キナーゼ阻害剤の医学的使用 | |
| EA037521B1 (ru) | Противогрибковые соединения и способы их получения | |
| CN102438975A (zh) | 取代的芳香化合物及其药物用途 | |
| JP2015536997A (ja) | カンナビノイド受容体媒介性化合物 | |
| TWI468396B (zh) | 環丙烷羧酸衍生物及其用途 | |
| JP2007520546A (ja) | モンテルカストナトリウムの安定な非晶質性形態 | |
| TWI752086B (zh) | 結晶型式 | |
| EP4405334B1 (en) | Sortilin inhibitors | |
| ES2437164T3 (es) | [4-(5-aminometil-fenil-piperidin-1-il]1H-indol-3-il-]-metanonas disustituidas | |
| KR20200020746A (ko) | 하이브리드 화합물 및 그 제조방법 | |
| TWI257389B (en) | Pharmaceutical compound | |
| KR20250149691A (ko) | 항섬유화 화합물의 고체 형태, 염 및 다형체 | |
| CN120569378A (zh) | 选择性血管紧张素ii化合物 | |
| KR20140000717A (ko) | 신규한 항-혈소판 화합물의 부가염 | |
| KR20210101164A (ko) | 하이브리드 화합물 및 그 제조방법 | |
| CN106554370A (zh) | 含有磷酸酯的达比加群衍生物及其制备方法和用途 | |
| TW201418202A (zh) | （３ｓ，３ｓ’）４，４’－二硫二基雙（３－胺基丁烷１－磺酸）與ｌ－離胺酸之新穎結晶相 | |
| CN104140398B (zh) | 甲基三唑希夫碱类结构的化合物、其制备方法和用途 | |
| CN104086494B (zh) | 末端双取代的甲基三唑希夫碱结构化合物、其制备方法和用途 | |
| CN104086495B (zh) | 末端双取代的三唑希夫碱结构化合物、其制备方法和用途 | |
| TWI876245B (zh) | (2R, 3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新穎酸加成鹽及晶形 | |
| CN103420982B (zh) | 达比加群酯衍生物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |